A research study of how safe a new medicine called NNC0519‑0130 is and to test its effect in people living with excess body weight with or without type 2 diabetes
NN9541-8116
Phase 1 other active
Quick answer
A research study of how safe a new medicine called NNC0519‑0130 is and to test its effect in people living with excess body weight with or without type 2 diabetes for Obesity, Type 2 Diabetes with either overweight or obesity is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Obesity, Type 2 Diabetes with either overweight or obesity
- Phase
- Phase 1
- Modality
- other
- Status
- active